Skip to main content
DOUBLE MEDICAL TECHNOLOGY INC. logo

DOUBLE MEDICAL TECHNOLOGY INC. — Investor Relations & Filings

Ticker · 002901 ISIN · CNE1000032W7 LEI · 836800DECKX5CGFNMD42 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 963 across all filing types
Latest filing 2022-08-23 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002901

About DOUBLE MEDICAL TECHNOLOGY INC.

https://www.double-medical.com

Double Medical Technology Inc. specializes in the development, manufacturing, and distribution of medical devices, with a primary focus on orthopedic solutions. The company's extensive product portfolio includes trauma fixation systems, spinal implants, joint prosthesis, and neurosurgical devices. Additionally, it provides specialized surgical instruments and advanced wound care products. Double Medical emphasizes research and innovation to deliver clinically effective solutions for complex musculoskeletal conditions. Its manufacturing processes adhere to international quality standards, ensuring the reliability of its implants and instruments used in hospitals and surgical centers worldwide. The company serves a global market, providing comprehensive support for orthopedic surgeons through its diverse range of reconstructive and regenerative medical technologies.

Recent filings

Filing Released Lang Actions
2022年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "大博医疗科技股份有限公司 2022 年半年度财务报告" which translates to "DaBo Medical Technology Co., Ltd. 2022 Semi-Annual Financial Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, cash flow statements, and changes in equity for the half-year period ending June 30, 2022. The report explicitly states it is a half-year financial report and includes comprehensive financial data and analysis for the period. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. There is no indication that this is an announcement of a report or a certification document. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-23 Chinese
北京德恒（厦门）律师事务所关于大博医疗科技股份有限公司2021年限制性股票激励计划终止实施和回购注销部分限制性股票的法律意见书
Regulatory Filings Classification · 95% confidence The document is a legal opinion letter issued by a law firm regarding the termination and repurchase/cancellation of a 2021 restricted stock incentive plan by a company. It discusses the legal compliance, approvals, authorizations, and procedures related to the stock incentive plan termination and repurchase. The document is not a financial report, earnings release, or management discussion, but a legal opinion related to a corporate action involving stock incentives. This type of document fits best under the category of Regulatory Filings (RNS), as it is a legal compliance and procedural filing rather than a financial report or announcement of voting results or capital changes. The document length is substantial and contains detailed legal analysis, not just an announcement or brief notice, so it is not an RPA. Therefore, the classification is RNS with high confidence.
2022-08-23 Chinese
独立董事关于控股股东及其他关联方占用公司资金、公司对外担保情况的专项说明和独立意见
Regulatory Filings Classification · 95% confidence The document is an independent opinion statement from the independent directors of a company regarding several specific matters: repurchase and cancellation of restricted shares, termination of a restricted stock incentive plan, half-year fundraising usage and deposit, and related party fund occupation and external guarantees. It references compliance with laws and regulations and provides opinions on these corporate governance and financial matters. The document is relatively short (1283 characters) and does not contain full financial statements or comprehensive financial data. It is not an annual or interim report, nor an earnings release. It is not a regulatory filing or certification letter but a formal independent directors' opinion on specific corporate governance and financial issues. This type of document fits best under the category of Regulatory Filings (RNS) as it is a regulatory announcement related to corporate governance and compliance, but does not constitute a full report or financial statement.
2022-08-23 Chinese
2022年半年度报告摘要
Interim / Quarterly Report Classification · 95% confidence The document is titled as a '2022 半年度报告摘要' which translates to '2022 Semi-Annual Report Summary'. It contains detailed financial data for the half-year period, including revenue, net profit, earnings per share, and shareholder information. The document is about 3,055 characters long, which is relatively short but contains substantive financial data and analysis for a period shorter than a full fiscal year. It is not merely an announcement or a certification but includes actual financial figures and performance metrics. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-23 Chinese
2022年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "大博医疗科技股份有限公司 2022 年半年度报告全文" which translates to "Double Medical Technology Inc. 2022 Semi-Annual Report Full Text." It contains detailed financial data, management discussion and analysis, business overview, product descriptions, financial metrics, and operational details for the first half of 2022. The presence of comprehensive financial statements, management analysis, and detailed business information for a half-year period clearly identifies this as an Interim / Quarterly Report. The document length is substantial (15,000 characters), and it contains actual financial data and analysis, not just an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR). H1 2022
2022-08-23 Chinese
关于回购注销部分限制性股票的公告
Transaction in Own Shares Classification · 95% confidence The document is a detailed announcement regarding the company's repurchase and cancellation of restricted shares under its 2018 and 2021 restricted stock incentive plans. It includes information about board and supervisory meetings, shareholder approvals, pricing adjustments, legal opinions, and the impact on share capital structure. The content focuses on share repurchase activities specifically related to restricted stock incentives, including the reasons, quantities, prices, and funding sources for the repurchase. This matches the definition of a Transaction in Own Shares (POS) filing, which covers company buybacks or sales of its own shares. The document is not a general regulatory filing, nor an annual or interim report, nor a proxy or voting announcement. It is a substantive announcement about share repurchase and cancellation, fitting the POS category with high confidence.
2022-08-23 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.